American Regent Inc (Shirley, NY) recently received FDA approval for 2 new indications for Venofer. The product was initially approved for use in the treatment of iron deficiency anemia in hemodialysis (HD) patients receiving an erythropoietin. Venofer now also is indicated for the treatment of iron deficiency anemia in peritoneal dialysis (PD) patients receiving an erythropoietin and in nondialysis chronic kidney disease (CKD) patients receiving or not receiving an erythropoietin. The product can be administered via an intravenous push (100-mg [HD] and 200-mg [CKD] doses) or by infusion (300- and 400-mg doses [PD]) depending on the indication. Venofer is available in 100-mg/5-mL single-dose vials. For more information, visit www.venofer.com, or call 800-645-1706.
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs